40 completed, 24 recruiting, 17 terminated, 16 active not recruiting. 66 Phase 2, 51 Phase 1, 5 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow talazoparib: new trials by email Literature Review of talazoparib trials Research Report on talazoparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Korea Post Marketing Surveillance (PMS) Study of Talzenna® Talzenna - Breast Neoplasms | Withdrawn | Pfizer | 2027-06-01 | 2026-09-14 | ||
| A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide Talazoparib with enzalutamide, Talazoparib - Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Recruiting | Prostate Cancer Clinical Trials Consortium | 126 | 2026-05-04 | 2026-08-21 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer ADT, Enzalutamide, Talazoparib - Prostate Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-06-03 | 2026-10-19 |
| Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC Atezolizumab, Talazoparib - Squamous Cell Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-05-01 | 2025-08-15 | |
| Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule - Metastatic Prostate Cancer | Phase 2 | Recruiting | Fundacion Oncosur | 78 | 2024-07-05 | 2026-10-05 |
| Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia NK cells, Talazoparib 1 MG [Talzenna] - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | German Cancer Research Center | 54 | 2024-06-01 | 2024-04-05 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer ZEN003694, Talazoparib - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Recruiting | Alexander B Olawaiye, MD | 33 | 2023-04-21 | 2026-06-18 |
| Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer Talazoparib Tosylate - Breast Cancer, Advanced Breast Cancer | Phase 2 | Withdrawn | Stanford University | 2023-02-23 | 2025-08-17 | |
| Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy Talazoparib, Topotecan, Gemcitabine - Acute Myeloid Leukemia | Phase 1 | Recruiting | Norman J. Lacayo | 34 | 2023-02-23 | 2026-04-22 |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2022-11-14 | 2026-09-25 |
| Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors Injections Subcutaneously Talazoparib, Oral capsules Talazoparib - Advanced or Recurrent Solid Tumors, Breast Neoplasm | Phase 1 | Withdrawn | Center Trials & Treatment | 2022-11-10 | 2023-03-29 | |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer Pidnarulex, Talazoparib - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Suspended | Peter MacCallum Cancer Centre, Australia | 48 | 2022-10-21 | 2023-12-11 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2022-07-11 | 2026-10-14 |
| StrataPATH™ (Precision Indications for Approved Therapies) lorlatinib, encorafenib + binimetinib, talazoparib - Cancer, Advanced Solid Tumor | Phase 2 | Terminated | Strata Oncology | 11 | 2022-04-29 | 2025-01-08 |
| Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature Talazoparib - HRD 100 Gene Expression High, Triple Negative Breast Cancer | Phase 2 | Unknown | University of Malaya | 55 | 2022-03-08 | 2022-03-21 |
| Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m Talazoparib - Metastatic Breast Cancer, Breast Neoplasms | Completed | Pfizer | 33 | 2021-12-17 | 2024-02-16 | |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours Talazoparib - Neuroendocrine Tumors | Phase 1 | Recruiting | Peter MacCallum Cancer Centre, Australia | 24 | 2021-12-08 | 2025-02-20 |
Showing 20 of 114. Sign in to see all of them.
Breast Neoplasms (29) · Prostatic Neoplasms (13) · Triple Negative Breast Neoplasms (13) · Neoplasms (12) · Ovarian Neoplasms (12) · Neoplasm Metastasis (9) · Fallopian Tube Neoplasms (6) · Leukemia, Myeloid, Acute (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Pancreatic Neoplasms (4) · Small Cell Lung Carcinoma (4) · Carcinoma, Renal Cell (3) · Carcinoma, Ovarian Epithelial (2)
Pfizer (29) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (7) · Dana-Farber Cancer Institute (3) · Massachusetts General Hospital (3) · Memorial Sloan Kettering Cancer Center (3) · Peter MacCallum Cancer Centre, Australia (3) · SWOG Cancer Research Network (3) · Jonsson Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · St. Jude Children's Research Hospital (2) · University Hospital, Caen (2) · Alexander B Olawaiye, MD (1) · Alliance Foundation Trials, LLC. (1) · American Society of Clinical Oncology (1)
United States (80) · United Kingdom (14) · France (12) · Australia (11) · Belgium (11) · Canada (11) · Spain (11) · South Korea (10) · Hungary (8) · Italy (8) · Poland (7) · Russia (7) · Germany (6) · Japan (6) · Netherlands (5)
A P Chen (2) · Ritesh Kotecha, MD (2) · Timothy A Yap (2) · Vassiliki Papadimitrakopoulou (2) · Agnes Jager, MD, PhD (1) · Alexander B Olawaiye, MD (1) · Alice P Chen, M.D. (1) · Alicia Morgans, MD (1) · Amado Zurita-Saavedra, MD (1) · Andrea Botticelli (1) · Atish Choudhury, MD PhD (1) · Aya Helali, MD, PhD (1) · Benjamin Lok, MD (1)
PMID 31461380, PMID 32379297, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 26410619, PMID 27406346, PMID 27406347, PMID 28851423, PMID 30110579, PMID 30124753, PMID 30345906, PMID 30563931, PMID 30689707, PMID 30792217, PMID 31724813, PMID 31770456, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33068284, PMID 33090333, PMID 33125909, PMID 33686631, PMID 33844595, PMID 34160752, PMID 34385584, PMID 34388386, PMID 34529000, PMID 34741021, PMID 34840720, PMID 35080190, PMID 35086719, PMID 35091441, PMID 35396812, PMID 35598186, PMID 35623341, PMID 35736816, PMID 35900726, PMID 35907135, PMID 35993306, PMID 36069821, PMID 36124924, PMID 36253484, PMID 36315917, PMID 36394849, PMID 36394867, PMID 36434554
2016 (5), 2018 (5), U10CA180888 (4), 2017 (3), 2023 (3), 2019 (2), P30CA006516 (1), P30CA016672 (1), P30CA033572 (1), P50CA083639 (1), R37CA282430 (1), UM1CA097452 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186709 (1)